INDP Indaptus Therapeutics
- 2.026
- -0.144-6.63%
Indaptus Therapeutics News
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
Express News | HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Indaptus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 322.54% HC Wainwright & Co. → $12 Reiterates Buy → Buy 09/20/2023 322.54% HC Wainwright & Co. →
Buy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough With Decoy20 Platform
Express News | Indaptus Therapeutics Unveils Details On Mechanism Of Action Data That Demonstrates The Company's Decoy Platform Induces, Matures Or Activates Multiple Immune Cell Types Involved In Anti-tumor Responses, At AACR Research Annual Meeting
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
Indaptus Therapeutics Previews Mechanism Of Action Data To Be Presented At The American Association For Cancer Research Annual Meeting
Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune celltypes involved in anti-tumor responsesNew data shows activity in M1 macrophages, natural killer ce
Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial Outlook
Indaptus Therapeutics GAAP EPS of -$1.83
Top Premarket Gainers
CCSC Technology International Holdings (CCTG) shares surged 35% Thursday premarket, extending Wednesday's rally. Turtle Beach Corp. (HEAR) shares rose 25% after the company reported it swung to Q4 ear
Indaptus Therapeutics: Q4 Earnings Insights
Indaptus Therapeutics (NASDAQ:INDP) reported its Q4 earnings results on Wednesday, March 13, 2024 at 07:30 AM.Here's what investors need to know about the announcement.EarningsIndaptus Therapeutics be
Express News | Indaptus Therapeutics FY EPS $(1.83) Beats $(1.95) Estimate; Cash Balance Of $13.4M Will Provide Runway Through Q3 Of 2024
Indaptus Therapeutics FY Loss/Shr $1.83 >INDP
Indaptus Therapeutics FY Loss/Shr $1.83 >INDP
Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update -- Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 -- In
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 74.5% to $1.85 during Monday's pre-market session. The company's market cap stands at $4.4 million. Dyadic International (NASDAQ:DYAI) s
Buy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 With Promising Developments
Top Midday Gainers
Quoin Pharmaceuticals (QNRX) said Monday that it received clearance from the US Food and Drug Administration to recruit subjects aged 14 and older into two ongoing clinical trials for QRX003, a potent
Indaptus Therapeutics Shares Rise 26% After Positive Trial Results for Decoy20
By Chris Wack Indaptus Therapeutics shares were up 26% to $2.63 in premarket trading after the company said it saw positive results from the second cohort of its Phase 1 trial for lead therapeutic ca
Express News | Indaptus Therapeutics Announces Results From Second Cohort Of Phase 1 Trial; Initiates Multi-Dose Cohort
CLSK, KOSS and TBLT Are Among Pre Market Gainers
Analysis
Price Target
No Data
